title: Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
abstract: Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures.
authors: Department of Health Services Research, School for Public Health & Primary Care, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. m.hiligsmann@maastrichtuniversity.nl
authors: Mickaël
authors: M
authors: Hiligsmann
authors: Annelies
authors: A
authors: Boonen
authors: Carmen D
authors: CD
authors: Dirksen
authors: Wafa
authors: W
authors: Ben Sedrine
authors: Jean-Yves
authors: JY
authors: Reginster
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D000069448:Denosumab; D016527:Drug Costs; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics* / Q000523:psychology; D058866:Osteoporotic Fractures / Q000191:economics / Q000517:prevention & control; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab